Letter | Published:

Dopamine mediates vagal modulation of the immune system by electroacupuncture

Nature Medicine volume 20, pages 291295 (2014) | Download Citation

Abstract

Previous anti-inflammatory strategies against sepsis, a leading cause of death in hospitals, had limited efficacy in clinical trials, in part because they targeted single cytokines and the experimental models failed to mimic clinical settings1,2,3. Neuronal networks represent physiological mechanisms, selected by evolution to control inflammation, that can be exploited for the treatment of inflammatory and infectious disorders3. Here, we report that sciatic nerve activation with electroacupuncture controls systemic inflammation and rescues mice from polymicrobial peritonitis. Electroacupuncture at the sciatic nerve controls systemic inflammation by inducing vagal activation of aromatic L-amino acid decarboxylase, leading to the production of dopamine in the adrenal medulla. Experimental models with adrenolectomized mice mimic clinical adrenal insufficiency4, increase the susceptibility to sepsis and prevent the anti-inflammatory effects of electroacupuncture. Dopamine inhibits cytokine production via dopamine type 1 (D1) receptors. D1 receptor agonists suppress systemic inflammation and rescue mice with adrenal insufficiency from polymicrobial peritonitis. Our results suggest a new anti-inflammatory mechanism mediated by the sciatic and vagus nerves that modulates the production of catecholamines in the adrenal glands. From a pharmacological perspective, the effects of selective dopamine agonists mimic the anti-inflammatory effects of electroacupuncture and can provide therapeutic advantages to control inflammation in infectious and inflammatory disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Severe sepsis and septic shock. N. Engl. J. Med. 369, 840–851 (2013).

  2. 2.

    & The “cytokine profile”: a code for sepsis. Trends Mol. Med. 11, 56–63 (2005).

  3. 3.

    The vagus nerve and the nicotinic anti-inflammatory pathway. Nat. Rev. Drug Discov. 4, 673–684 (2005).

  4. 4.

    Adrenal insufficiency in sepsis. Curr. Pharm. Des. 14, 1882–1886 (2008).

  5. 5.

    et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662–664 (1987).

  6. 6.

    , & Novel strategies for the treatment of sepsis. Nat. Med. 9, 517–524 (2003).

  7. 7.

    , , & Scientific and clinical challenges in sepsis. Curr. Pharm. Des. 15, 1918–1935 (2009).

  8. 8.

    Points of control in inflammation. Nature 420, 846–852 (2002).

  9. 9.

    et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit. Care Med. 29, 503–510 (2001).

  10. 10.

    et al. Vagus nerve stimulation attenuates the systemic inflammatory response to LPS. Nature 405, 458–462 (2000).

  11. 11.

    et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 203, 1623–1628 (2006).

  12. 12.

    et al. Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis. J. Immunol. 187, 718–725 (2011).

  13. 13.

    et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J. Vasc. Surg. 36, 1231–1236 (2002).

  14. 14.

    et al. Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-α production, and protects againts splanchic artery occlusion shock. Shock 25, 500–506 (2006).

  15. 15.

    et al. α7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation. J. Cell. Mol. Med. 13, 3774–3785 (2009).

  16. 16.

    et al. The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 130, 1822–1830 (2006).

  17. 17.

    et al. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 330, 811–815 (1994).

  18. 18.

    et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216–1221 (2004).

  19. 19.

    et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J. Infect. Dis. 191, 2138–2148 (2005).

  20. 20.

    et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch. Intern. Med. 172, 1444–1453 (2012).

  21. 21.

    & Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst. Rev. CD003281 (2004).

  22. 22.

    & Patient characteristics for outpatient acupuncture in Beijing, China. J. Altern. Complement. Med. 10, 565–572 (2004).

  23. 23.

    et al. Acupuncture for stroke rehabilitation. Cochrane Database Syst. Rev. CD004131 (2006).

  24. 24.

    et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat. Neurosci. 13, 883–888 (2010).

  25. 25.

    , & Acupuncture: does it alleviate pain and are there serious risks? A review of reviews. Pain 152, 755–764 (2011).

  26. 26.

    et al. β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J. 25, 4476–4485 (2011).

  27. 27.

    , , & The innervation of the adrenal gland. III. Vagal innervation. J. Anat. 163, 173–181 (1989).

  28. 28.

    et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384–388 (2003).

  29. 29.

    , , & α7-nicotinic receptor mediates vagal induction of splenic norepinephrine. J. Immunol. 186, 4340–4346 (2011).

  30. 30.

    & Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 258, 193–198 (1991).

  31. 31.

    et al. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. Br. J. Clin. Pharmacol. 25, 17–21 (1988).

  32. 32.

    , & Dopaminergic stimulation of prolactin release. Nature 285, 243–246 (1980).

  33. 33.

    & Solubilisation of high-affinity dopamine receptors. Nature 279, 72–74 (1979).

  34. 34.

    et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit. Care Med. 33, 2451–2456 (2005).

  35. 35.

    & Behavioral models of pain states evoked by physical injury to the peripheral nerve. Neurotherapeutics 6, 609–619 (2009).

  36. 36.

    , , & The spared nerve injury (SNI) model of induced mechanical allodynia in mice. J. Vis. Exp. 3092 (2011).

  37. 37.

    , , & Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock 28, 582–588 (2007).

  38. 38.

    et al. Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol. Dis. 41, 385–397 (2011).

  39. 39.

    , & Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397, 710–713 (1999).

Download references

Acknowledgements

We thank P. Morcillo, J.M. Inclan-Rico and J.R. Berlin for their comments and suggestions and M. Marks (University of Colorado) and B. Kobilka (Stanford University) for the α7nAChR and β2AR knockout mice. R.T.-R. was supported by the University Autónoma Benito Juarez de Oaxaca. M.d.R.T.-B. was supported by the Mexican National Council for Science and Technology. L.U. is supported by the faculty program of the Department of Surgery of the New Jersey Medical School, the Foundation of University of Medicine and Dentistry of New Jersey and US National Institutes of Health grant RO1-GM084125.

Author information

Affiliations

  1. Laboratory of Anti-inflammatory Signaling, Department of Surgery, Rutgers University New Jersey Medical School, Newark, New Jersey, USA.

    • Rafael Torres-Rosas
    • , Ghassan Yehia
    • , Geber Peña
    • , Priya Mishra
    • , Maria del Rocio Thompson-Bonilla
    •  & Luis Ulloa
  2. Medical Research Unit on Immunochemistry, National Medical Center Siglo XXI, Mexico City, Mexico.

    • Rafael Torres-Rosas
    • , Lourdes Andrea Arriaga-Pizano
    •  & Armando Isibasi
  3. The Institute for Social Security and Services for the State's Employees Research Institute, Mexico City, Mexico.

    • Maria del Rocio Thompson-Bonilla
  4. Laboratory of Immunobiology, Hospital Juárez de México, Mexico City, Mexico.

    • Mario Adán Moreno-Eutimio
  5. Center of Immunology and Inflammation, Rutgers University New Jersey Medical School, Newark, New Jersey, USA.

    • Luis Ulloa

Authors

  1. Search for Rafael Torres-Rosas in:

  2. Search for Ghassan Yehia in:

  3. Search for Geber Peña in:

  4. Search for Priya Mishra in:

  5. Search for Maria del Rocio Thompson-Bonilla in:

  6. Search for Mario Adán Moreno-Eutimio in:

  7. Search for Lourdes Andrea Arriaga-Pizano in:

  8. Search for Armando Isibasi in:

  9. Search for Luis Ulloa in:

Contributions

R.T.-R., G.Y., G.P., P.M. and M.d.R.T.-B. performed the experiments, prepared the figures and revised the article. M.A.M.-E., L.A.A.-P. and A.I. contributed to the design of the study and revised the paper. L.U. designed and directed the study and wrote the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Luis Ulloa.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–3

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.3479

Further reading